The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Webinar 'Artificial Intelligence in Medical Imaging'
https://www.youtube.com/watch?v=xwgr5QuL_Ig
Interesting points:
Americans experience 12 million diagnostic errors a year
700 Billion medical images/year in US alone (many modalities/cases)
Is there a nodule?
Radiology is one of the specialties most liable to claims of medical negligence. Most often, plaintiff's complaint against a radiologist will focus on a failure to diagnose.
From 31:23 timestamp:
Challenges of using AI in medical imaging
'We see 3 challenges'
1. Lack of publicly available image repositories
2. Lack of publicly available image repositories
3. Lack of publicly available image repositories
'We do not have publicly available image repositories. That's a big problem in medical imaging.' (See Q&A at end of webinar too)
We need a large enough collection of clinically relevant cases and DICOM Images and metadata otherwise you cannot exploit AI. They also need to be labelled and curated by several experts, not just one.
^
This is where the collaboration with Mayo clinic is so important imv. Access to the data they have is invaluable.
And the need for IB's LSN (Liver Surface nodularity) software - By accessing nodules or bumps on the liver's surface, the technology can aid clinicians in the diagnosis and staging of the disease with a low risk assessment using CT images.
My hope (aside from increasing revenue generated from sales of FDA/CE approved tech) is some form of M&A in the not too distant future or a strategic investment maybe from 1 of the big boys with interest in IB's 'gad-free' tech or tumour software? (huge Contrast Agents market)
Also possibility of additional grants from NIH as IB being the 'national standard' in USA (further from the $2.6m awarded in June).
Anyone guess what the installation $ from Keck Medical Centre and Montgomery Cancer Centre would be?
I was thinking between $40-60k each, maybe? Not sure.
Note Mayo want 4% on-going royalty on each future sale of IB Trax, including $20k royalty on the initial commercial installation.
Note too IBs tweet of 6000 hospitals and 7000 imaging centers should have access to the recommended standard for brain tumor imaging (US only exc global).
If 6000 hospitals alone (not inc imaging centers, US only) followed suit with Keck & Monty at say even $20k per installation that would = $120m
https://www.marketwatch.com/press-release/contrast-agents-market-research-with-size-growth-manufacturers-segments-and-2026-forecasts-research-2020-12-01?tesla=y#:~:text=Press%20Release-,Contrast%20Agents%20Market%20Research%20With%20Size%2C%20Growth%2C%20Manufacturers%2C,Segments%20And%202026%20Forecasts%20Research&text=The%20Global%20Contrast%20Agents%20Market,in%20the%20given%20forecast%20period.
The Global Contrast Agents Market is expected to exceed more than US$ 6.0 billion by 2024 and will grow at a CAGR of more than 4% in the given forecast period.
The major driving factors of Global Contrast Agents Market are as follows:
? Growing number of private and public diagnostic centers.
? Increasing approvals for contrast agents.
The restraining factors of Global Contrast Agents Market are as follows:
? Side Effects related with contrast agents.
The Contrast Agents Market has been segmented as below:
The Contrast Agents Market is Segmented on the lines of Application Analysis, Products Analysis, Route of Administration Analysis, Medical procedure Analysis, Indication Analysis and Regional Analysis. By Application Analysis this market is segmented on the basis of Radiology, Interventional cardiology and Interventional radiology. By Products Analysis this market is segmented on the basis of Gadolinium-based contrast media, Iodinated contrast media, High-osmolar contrast media (HOCM), Low-osmolar contrast media (LOCM) and Barium-based contrast media. By Route of Administration Analysis this market is segmented on the basis of Urethral, Oral, Rectal, Injection its covers Intra-arterial & Intravenous.
^
Looking forward to updates on IBs 'Gad-free' application/patent etc.
Shock Wave vs Laser. The debate continues. Speaker: Dr. Ran Katz.
https://www.youtube.com/watch?v=oE41iMH9YdU
Interesting webinar detailing the use of ESWL (Extracorporeal shock wave lithotripsy).
From 42:12 minutes on webinar, talks about Covid and the challenges and opportunities.
Short story is ESWL is here to stay.
It seems logical to me, it would be better to know if ESWL was going to work for the patient before undergoing the procedure - not only factoring the cost and/or further costs for further treatments but esp during this time of Covid i.e. knowing whether the treatment is going to be a success or not (based on AI statistical analysis) would remove unnecessary hospital visits, costs and help define the correct treatment.
Obv. knowing the most efficient level of shockwave needed too will reduce (or eliminate) the number of further treatments needed i.e. SC main feature - esp when hospitals are overstretched.
Posted this in May. Worth a watch maybe.
youtube.com/watch?v=NC5Gzgd7UOY
"Vision Opportunities in Healthcare," a Presentation from Woodside Capital Partners
Interesting talk of the M&A space and benefits of computer vision in Healthcare. A lot of money/investment in this space.
'what we've done is segment the application areas into these four primary areas where we think computer vision is going to have the biggest impact on the market - so imaging diagnostics seems to be the major one and you know when you stop to think about it training a system on a bunch of radiological scans using today's deep learning approaches you know it's sort of for those who understand how this works it's intuitively obvious that it's not going to take very long before we have systems that can outperform the best radiologists out there'
Great to see further updates to IB clinic software. Hoping for more news re: Stonechecker v2.0 with info regarding interest.
If IB brain tumor software is the recommended standard, so much potential here surely. Some great info in IQAI's twitter feed.
https://twitter.com/IQAI_IB/status/1297933932143484930 (tweet from Aug shows potential, exc. global).
Also here is the link to the gad-free patent (not sure if already posted).
https://worldwide.espacenet.com/publicationDetails/biblio?CC=US&NR=2019122348A1&KC=A1&FT=D&ND=3&date=20190425&DB=EPODOC&locale=en_EP#
https://www.brighttalk.com/webcast/17202/440378?utm_campaign=Microsoft&utm_content=144911592&utm_medium=social&utm_source=twitter&hss_channel=tw-194595335
Secure by Design: IoT Security Lifecycle Management with Microsoft Azure Sphere
Presented by
Josh Nash, Microsoft and James Penney, Device Authority
https://revcycleintelligence.com/news/healthcare-merger-and-acquisition-activity-increased-in-q3-2020
Not forgetting the possibility of M&A activity. That's the end-game anyway. Keep these in my SIPP.
GLA
Excerpt from final results RNS:
Our expertise of translating novel technologies into routine clinical practice sets us apart from other medical imaging companies. As we move forward in 2020, we will continue to offer services to researchers who may need assistance in translating their research and technologies. Those services, whether software development, regulatory assistance, or marketing support, allows us to assess the commercialization potential of these new technologies for possible merger and/or acquisition opportunities.
Finally, we remain alert to the myriad of new companies creating innovative solutions that solve healthcare problems and aid patients. While we are excited about our organic growth potential, we recognize that merger and acquisition activity may accelerate revenue generation, fulfill technical gaps, and a potentially faster time to market. Expanding our footprint in medical imaging to better serve patients remains our unwavering goal, and we will remain aggressive in this pursuit.
Thanks for posting CHELMOCHASER.
Excerpt:
Genedrive share price investment potential
Still, from an investment perspective, I think the Genedrive share price looks attractive. One of the most common reasons why early-stage healthcare companies fail is lack of funds. That’s not something investors here need to be worried about right now.
At the end of June, Genedrive had £8.2m of cash on the balance sheet. I think that could be enough to sustain the business for at least two years. The company should have reached the revenue stage by that point. From there on, the sky could be the limit for Genedrive.
As such, while the Genedrive share price has fallen in recent months, I think the firm’s fundamentals look much stronger today than they were at the beginning of the year. If the company’s testing products are approved around the world, the revenue opportunity could be substantial.
Good post isb1974. Remain hopeful but nice to see some balance to the board as highlighted by criticism from safestocks. My short-term concern (aside from Covid) is the US highs (although some correction going on) and esp the VIX share price (fear index) currently @ 31.00 with Goldman Sachs saying market flashing warning signal. Hopefully they are wrong but there is a lot of risk just now short-term with US elections, Brexit, Etc and Tesla valuation still way too high imv.
Thanks for posting Klick.
Here's a better link without need to download/install apk to read full article.
https://auto.sina.cn/news/hy/2020-07-06/detail-iircuyvk2098715.d.html
Anyone have any good links to other exchanges where Velocys are listed ?
(other than marketwatch.com)
Here's one i found on German Exchange - currently up 4.47% @ 0.13 euros.
https://www.marketwatch.com/investing/stock/o7n?countrycode=de&iso=xfra
Interesting GMT Capital Corp have closed their short. Hopefully a good omen with court case etc?
https://www.fca.org.uk/markets/short-selling/notification-and-disclosure-net-short-positions
youtube.com/watch?v=NC5Gzgd7UOY
"Vision Opportunities in Healthcare," a Presentation from Woodside Capital Partners
Interesting talk of the M&A space and benefits of computer vision in Healthcare. A lot of money/investment in this space.
'what we've done is segment the application areas into these four primary areas where we think computer vision is going to have the biggest impact on the market - so imaging diagnostics seems to be the major one and you know when you stop to think about it training a system on a bunch of radiological scans using today's deep learning approaches you know it's sort of for those who understand how this works it's intuitively obvious that it's not going to take very long before we have systems that can outperform the best radiologists out there'
GoldAnOil, according to recent RNS, GM held tomorrow at 10am.
Thanks for posting Crystalball, I too would be interested to know how this would play out.
GENERAL MEETING
A circular including notice of the General Meeting (the "Circular") will be sent to Shareholders later today convening the General Meeting to be held at 10:00 a.m. on 23 April 2020. Details of the General Meeting, as well as form of proxy will be sent to shareholders with the Circular. The Circular will also be available on the Company's website, www.avacta.com once posted.
Trying to catch up here on latest developments. What are the odds i post about patent infringement on the Thurs last week and we get a lawsuit on the Monday. lol. Good find gonebroke.
M.E. said in April we believe big folks have stepped on our IP and are engaged with discussions with them. He also said Nanoco's QD's are better than the dots Samsung are able to produce internally...makes you wonder.
Would Samsung be uneasy about having to reveal their manufacturing processes? Just a thought?
Another link relating same Samsung breakthrough.
https://phys.org/news/2019-11-samsung-efficient-quantum-dots-heavy.html
I agree it's possible thomasbrowne. When M.E. talked about it, my thought of 'the big folks' must be Samsung - the list must be few anyway.
Although similar in their use of HF acid, I think the processes in the patents are different. Will keep looking.
e.g. here's an interesting graph shown in this patent (or very similar) as appears in the link above. Although I presume this is just taken from known R&D already published? Not a patent expert.
https://patents.google.com/patent/US20130075692A1/en?q=semiconductor+nanoparticle-based&q=light+emitting&q=materials&oq=semiconductor+nanoparticle-based+light+emitting+materials